Guo, Angela H.
Baliira, Rachael
Skinner, Mary E.
Kumar, Surinder
Andren, Anthony
Zhang, Li
Goldsmith, Robert S.
Michan, Shaday
Davis, Norma J.
Maccani, Merissa W.
Day, Sharlene M.
Sinclair, David A.
Brody, Matthew J.
Lyssiotis, Costas A.
Stein, Adam B.
Lombard, David B.
Funding for this research was provided by:
National Institute on Aging (T32AG000114, R37AG028730, R37AG028730)
National Institute of General Medical Sciences (T32GM113900, R25GM086262, R01GM101171, R01GM101171, R01GM101171)
National Institute of Environmental Health Sciences (R21ES032305, R21ES032305, R21ES032305)
National Cancer Institute (R01CA248160, R01CA248160, R01CA248160)
National Heart, Lung, and Blood Institute (R00HL136695, R00HL136695)
Article History
Received: 24 December 2021
Accepted: 11 July 2022
First Online: 18 July 2022
Competing interests
: DAS is a consultant to MetroBiotech, a company developing NAD + boosters to treat rare diseases; a complete list of DAS activities is at ExternalRef removed. CAL has received consulting fees from Astellas Pharmaceuticals and is an inventor on patents pertaining to Kras regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting the GOT1 pathway as a therapeutic approach. DBL reports ownership of the equivalent in voting stock or share of ABBV and GILD. All other authors do not have any conflict of interests.